Riltide Medicines

Riltide Medicines is an AI-driven biotechnology company founded in 2024 and based in Beijing, China, with an additional entity in Singapore. The company specializes in the discovery and development of innovative oral small-molecule therapeutics, with a primary focus on autoimmune and inflammatory diseases such as systemic lupus erythematosus and inflammatory bowel disease. Riltide integrates advanced artificial intelligence with expert drug discovery practices, utilizing its proprietary 'Logos' platform—an evolvable reasoning engine designed for rational molecular design. The company's pipeline includes novel cyclic GMP-AMP synthase (cGAS) inhibitors, which are currently in pre-clinical development. Riltide is backed by prominent investors, including NRL Capital (New Leaf Capital) and Qingtan Investment.